Free Newsletter
New approach to vaccine development
The Guardian covers the development of a new generation of virus-vectored vaccines that promise to take on a number of diseases like malaria. Instead of a traditional approach using weakened virus to produce antibodies that fight disease, researchers are adding the genetic code of molecules into the DNA of the virus. That approach is believed to be more effective in supporting a strong immune response. Efficacy trials for the new approach may be mounted in Africa in three to four years, after researchers have had a chance to test a malaria vaccine. The work is being funded by the Bill and Melinda Gates Foundation, which has funneled huge sums into the science.
- read the article on vaccine research from The Guardian
Related Articles:
Gates Foundation restructures, refocuses. Report
Gates adds $287M to HIV vaccine research. Report
Comments
Post new comment
Paid Research Reports
- The Specialty Pharma Market Outlook: Key players, new company growth models and emerging opportunities
- Investigating Clinical Trial Costs: Comparative analysis of trial cost components in key geographies
- Clinical Trial Recruitment Strategies: Optimizing patient recruitment and retention in late stage clinical trials
- Pipeline Insight: Therapeutic Cancer Vaccines - Prospect of first approval set to reinvigorate interest from major companies
- Stakeholder Opinions: Vaccines in Emerging Markets (Asia) - Opportunities in China, India, South Korea and Taiwan
- Big Pharma Performance Before, During and Beyond the Global Recession
SHARE
WITH: